Chapters
| Status | Drug name | NICE TAs | Comments |
|---|---|---|---|
 | Alendronic acid 70mg effervescent tablets (Binosto®) | Third line option in individuals who have not tolerated first line alendronate tablets and second line risedronate tablets and in whom a bone-sparing agent is still considered clinically necessary | |
| Alendronic acid tablets | ||
 | Calcitonin injection (Salmon) | ||
| Calcitonin nasal spray (Salmon) | ||
| Cetrorelix injection | ||
 | Denosumab injection (Prolia®) | ESCA | |
| Denosumab injection (Xgeva®) | ||
| Disodium etidronate (Didronel®) | ||
| Disodium etidronate tablets | ||
| Disodium pamidronate injection | ||
| Ibandronic acid injection | ||
| Ibandronic acid tablet | ESCA | |
| Parathyroid hormone injection | ||
| Risendronate tablets | ||
| Romosozumab (Evenity®) | ||
| Sodium clodronate capsules | ESCA | |
| Teriparatide injection | ||
| Zoledronic acid injection |
Drug status key
Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.
Grey
Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.
Red
Initiation and maintenance of prescribing by specialists only.
Amber
Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.
Green
Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.
Blue
Under review at University Hospitals Birmingham NHS Foundation Trust.
